

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for TL309566V

Selenium Binding Protein 1 (SELENBP1) Human shRNA Lentiviral Particle (Locus ID 8991)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Selenium Binding Protein 1 (SELENBP1) Human shRNA Lentiviral Particle (Locus ID 8991)
Locus ID:	8991
Synonyms:	EHMTO; HEL-S-134P; hSBP; LPSB; MTO; SBP56; SP56
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	SELENBP1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	<u>NM 001258288, NM 001258289, NM 003944, NM 003944.1, NM 003944.2, NM 003944.3, NM 001258288.1, NM 001258289.1, BC009084, BC009084.1, BC032997, NM 003944.4, NM 001258289.2, NM 001258288.2</u>
UniProt ID:	<u>Q13228</u>
Summary:	This gene encodes a member of the selenium-binding protein family. Selenium is an
	essential nutrient that exhibits potent anticarcinogenic properties, and deficiency of selenium may cause certain neurologic diseases. The effects of selenium in preventing cancer and neurologic diseases may be mediated by selenium-binding proteins, and decreased expression of this gene may be associated with several types of cancer. The encoded protein may play a selenium-dependent role in ubiquitination/deubiquitination-mediated protein degradation. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Apr 2012]



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

	Selenium Binding Protein 1 (SELENBP1) Human shRNA Lentiviral Particle (Locus ID 8991) – TL309566V
Performance Guaranteed:	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
	For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US